Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines in cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, with potential for expansion in the medium to long term.

Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, with potential for medium to long-term expansion. The partnership leverages the growing demand for combination therapies in Southeast Asia's rapidly expanding pharmaceutical market.

Brodsky & Smith law firm announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and pay fair value to shareholders. The investigations involve Veris Residential ($19.00/share), XOMA Royalty ($39.00/share), Organon ($14.00/share), and RE/MAX Holdings ($13.80/share or stock election).

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

Investor rights law firm Halper Sadeh LLC is investigating four major companies for potential securities law violations and breaches of fiduciary duties. The investigations concern McCormick & Company's merger with Unilever's Foods business, Leggett & Platt's sale to Somnigroup International, Organon & Co.'s sale to Sun Pharmaceutical, and Kennedy-Wilson Holdings' sale to a consortium led by its CEO. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

Sirius XM is in preliminary discussions to acquire iHeartMedia in a potential merger of America's largest satellite radio provider and radio station owner. Other major deals include Eli Lilly acquiring AI startup Profluent for up to $2.25 billion, Sun Pharmaceutical acquiring Organon for $11.75 billion, and Uber purchasing Hong Kong-based FlyTaxi. Meanwhile, several companies filed for bankruptcy including Wren Kitchens, FreshRealm, and Smokey Bones BBQ.

Investor rights law firm Halper Sadeh LLC is investigating four pharmaceutical and real estate companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

Organon & Co. shares surged 16.87% to $13.16 after Sun Pharmaceutical Industries agreed to acquire the women's health company in an all-cash deal valued at $14 per share. The acquisition, expected to close in early 2027, comes as relief for Organon, which has struggled since its 2021 spinoff from Merck with $8 billion in long-term debt and declining profitability.

U.S. stock futures fell on Monday as President Trump canceled Iran talks, citing divisions within Tehran. The market awaits the Federal Reserve's Wednesday meeting with 100% likelihood of unchanged rates. Key movers include Organon jumping 15% on a $11.75B acquisition deal, SAP rising 6.14% on cloud adoption acceleration, and Cheetah Net plummeting 22.12% following a reverse stock split announcement.

Sun Pharmaceutical Industries is finalizing a $12 billion binding offer for Organon & Co., which would mark the largest overseas acquisition by an Indian pharmaceutical company. Sun Pharma has completed three months of due diligence and is arranging financing with multiple global banks before submitting a firm bid in the coming weeks. The acquisition aligns with Sun Pharma's strategy to become a more innovation-driven, branded pharmaceutical player.

Sio Capital Management initiated a new $24.53 million position in Organon (OGN), purchasing 3.4 million shares at $6.03 per share. Despite the stock being down 61% over the past year, the investment signals potential turnaround opportunity as the pharmaceutical company focuses on stabilizing operations with flat 2026 guidance, supported by $1.9 billion in adjusted EBITDA despite declining revenues and profitability.

KDventures announced that Organon has discontinued development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was acquired as part of the Forendo portfolio company purchase in 2021. This marks the discontinuation of both drug candidates from the acquisition, following the earlier discontinuation of OG-6219 for endometriosis in July 2025. KDventures will write off its entire remaining book value of potential additional purchase considerations.